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Abstract
Several in vitro and in vivo models have revealed the key role of CXCR4/CXCL12 axis in tumor-stroma interactions.
Stromal cells present in the tumor microenvironment express high levels of CXCL12 protein, directly stimulating pro-
liferation andmigration of CXCR4-expressing cancer cells. This specific prosurvival influence of stromal cells on tumor
cells is thought to protect them from cytotoxic chemotherapy and is postulated as a possible explanation for the
minimal residual disease in hematological and solid cancers. Therefore, CXCR4/CXCL12 signaling is an attractive
therapeutic target in cancer, as proven in preclinical leukemia mouse models, where CXCR4 inhibition sensitized
cancer cells to conventional chemotherapy. This study investigates whether inhibition of CXCR4 with the specific
inhibitor AMD3100 sensitizes human prostate cancer cells to docetaxel. We showed that both mouse and human
stromal cell lines have a protective effect on PC3-luc cells by promoting their survival after chemotherapy. Further-
more, we demonstrated that AMD3100 sensitizes PC3-luc cells to docetaxel. In a subcutaneous xenograft mouse
model of human prostate carcinoma, we showed that a combination of docetaxel and AMD3100 exerts increased
antitumor effect compared with docetaxel alone. We concluded that CXCR4 inhibition chemosensitizes prostate
cancer cells, both in vitro and in vivo. To explore the relevance of these findings, we analyzed CXCR4 expression levels
in humanprostate cancer samples.We found that cancer cells present in bonemetastatic lesionsexpress higherCXCR4
levels relative to the cells present in primary tumors and lymph nodemetastatic lesions. These findings underscore the
potential of CXCR4 inhibitors as chemosensitizing agents.
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Introduction
The pivotal role of the chemokine receptor 4 (CXCR4) and its ligand
(CXCL12) in the proliferation and metastasis of tumor cells, induc-
tion of angiogenesis, and invasive tumor growth has been recognized
for over a decade [1]. CXCR4 expression is an independent prog-
nostic factor for poor overall survival not only in prostate cancer [2]
but also in melanoma [3] and metastatic colorectal cancer [4]. In pa-
tients with breast cancer, a high expression of CXCR4 is associated
with poor survival [5].
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Stromal cells are thought to be amajor source of CXCL12. In the bone
marrow, constitutive CXCL12 secretion by stromal cells is crucial for
homing and sustaining CXCR4-expressing hematopoietic stem and
progenitor cells (HSCs and HPCs) in their niches [6,7]. As shown in
acute myeloid leukemia (AML) human xenotransplant mouse models,
leukemic cells also localize in CXCL12-rich niches of bone marrow,
where the protective microenvironment favors their growth and survival
during cytotoxic treatment [8]. In murine models of chronic myeloge-
nous leukemia [9], acute myeloid leukemia [10], and chronic lympho-
cytic leukemia [11], it has been shown that CXCR4 antagonists—such
as the small-molecule AMD3100 (plerixafor—a drug that blocks the
binding pocket of CXCR4), CXCL12 analogs (CTCE-9908), and
T140 analogs (peptidic CXCR4 antagonists)—can disrupt tumor-
stroma interactions and mobilize leukemic cells to the peripheral blood,
making them more sensitive to conventional anticancer drugs.
Interestingly, solid tumors also interact with the stromal micro-
environment. In metastatic mouse models of osteosarcoma and mela-
noma [12] and in a transgenic breast cancer mouse model [13], it
is shown that cancer cells metastasize preferentially to CXCL12-rich
niches. A study in a prostate cancer mouse model revealed that prostate
cancer homes to the bone marrow through CXCR4/CXCL12 axis by
competing with hematopoietic stem cells for the endosteal niches, from
where both cell types can bemobilized byCXCR4 inhibition [14]. Also,
in a human breast cancer xenograft mouse model, in which cancer-
associated fibroblasts were coimplanted, it was shown that breast cancer
cells actively recruit stromal cells to the tumor, which, in turn, recruit
CXCR4-positive bone marrow–derived progenitor cells. This stimulates
angiogenesis and vasculogenesis and supports tumor growth [15]. Strik-
ingly, cancer-associated fibroblasts, but not normal fibroblasts, were
shown to have the ability to promote progression of tumorigenesis of
prostate epithelium in vivo and in an in vitro coculture system [16].
The cancer cell microenvironment has recently become a topic of
interest in prostate cancer research as well. Prostate cancer is the most
common cancer in men and the second leading cause of cancer-related
death in Western countries [17]. The treatment of localized prostate
cancer consists of surgery or radiotherapy with or without hormonal
therapy, whereas in advanced disease, hormonal therapy based on andro-
gen depletion is indicated [18,19]. For castrate-refractory prostate can-
cer patients with advanced disease, standard chemotherapy regimens
with docetaxel [20] and cabazitaxel are available [21]. However, the
castrate-refractory prostate cancer has a striking preference for skeletal
localization of distant metastasis [22]. It has been postulated that the
bone marrow stromal microenvironment provides a protective niche
for cancer cells, leading to therapy resistance and possibly relapse of dis-
ease [23]. Therefore, novel treatment options in prostate cancer, which
target the cancer cell–microenvironment interaction, are of interest.
In this study, we questioned whether targeting the CXCR4/
CXCL12 axis in prostate cancer interferes with the protective tumor-
stromal microenvironment interactions and sensitizes cancer cells to
docetaxel chemotherapy. Moreover, we aimed to explore the potential
relevance of our findings by analyzing CXCR4 expression levels in
patient samples of primary and metastatic prostate cancer.
Materials and Methods
Cell Lines
Luciferase-transfected human metastatic prostate cancer cell line
(PC3-luc; Caliper Life Sciences, ’S-Hertogenbosch, the Netherlands)
was cultured in Roswell ParkMemorial Institute (RPMI) 1640medium
with 10% fetal bovine serum (FBS; Perbio Sciences, Breda, the
Netherlands) and the breast cancer cell line (MDA-MB-231; ATCC,
Wesel, Germany), included as a positive control, was cultured in
Dulbecco modified Eagle mediumwith 10% FBS and 1% L-glutamine.
Human bone marrow–derived stromal cell line (HS27a; ATCC) was
maintained in RPMI 1640 with 10% FBS and the mouse bone marrow–
derived stromal fibroblasts cell line (MS5; ATCC) in α-minimum
essential medium with 10% FBS. All cell lines were maintained at
37°C with 5%CO2 in a humidified atmosphere. All media and supple-
ments were obtained from Invitrogen (Bleiswijk, the Netherlands).
Drug Sensitivity in the In Vitro Coculture Model
PC3-luc cells (or control cells MDA-MB-231) cells prelabeled with
red fluorescent dye (DiI; Invitrogen) were plated in 24-well plates on
glass slides with or without precultured stromal monolayer (MS5 or
HS27a). Cells were treated with docetaxel (LC Laboratories, Woburn,
MA) in concentrations ranging from 0.1 to 1 μM for 40 hours with or
without 25 μg/ml AMD3100 (Sigma, Zwijndrecht, the Netherlands)
or with docetaxel with or without a 1:100 anti-hCXCL12 antibody
(cross-reactive with mouse CXCL12 according to datasheet specifi-
cations; Abcam, Cambridge, United Kingdom). Glass slides were
collected after treatment, fixed, and stained with 4′,6-diamidino-2-
phenylindole (DAPI; Sigma). Tumor cell viability was assessed with
nuclear DAPI staining based on the observation of the nuclear structure
(intact vs fragmented nuclei). DiI staining was used to identify tumor
cells in coculture.
Cell Adhesion in the In Vitro Coculture Model
PC3-luc cells prelabeled with DiI were plated in 24-well plates
on glass slides with MS5 monolayer in the presence or absence of
25 μg/ml AMD3100. The glass slides were collected and fixed at 0
to 24 hours. The total number of adherent tumor cells was counted
by fluorescent microscopy.
Cell Migration Assay
Transwell inserts (pore size, 8 μm) and lower wells were coated with
15 μg/ml collagen type I, incubated for 1 hour at 37°C and blocked
overnight with phosphate-buffered saline (PBS) containing 1% bovine
serum albumin at 4°C. Subsequently, the blocking buffer was removed,
and the lower wells were loaded with 300 μl of 10−7 M CXCL12 in
serum-free RPMI or serum-free RPMI only (negative control).
PC3-luc cells were serum-starved overnight and harvested with
enzyme-free cell detaching buffer. The cells were incubated with
25 μg/ml AMD3100 in serum-free RPMI or serum-free RPMI only
for 30 minutes at 37°C. Inserts were loaded with 12 × 104 cells in
150 μl per condition and were allowed to migrate for 4.5 hours at
37°C. After migration, nonmigrated cells were removed with a cotton
swab wetted in PBS. Cells at the bottom surface were fixed in 75%
methanol/25% acidic acid for 20 minutes at room temperature, stained
with 0.25% Coomassie blue in 45% methanol/10% acidic acid for
20 minutes at room temperature, washed, air-dried, and mounted on
a microscope slide. The number of migrated cells was calculated by
counting cells from five fields of view per slide, with 40× magnification
with a counting grid.
CXCR4 Membrane Expression
PC3-luc or MDA-MB-231 cells were incubated with 1:100 polyclonal
rabbit anti-hCXCR4 antibody (Abcam) or with PBS (2.7 mM KCl,
potassium 1.8 mM KH2PO4, 137 mM NaCl, 10.1 mM Na2HPO4,
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pH 7.4) for 45 minutes on ice, followed by 30 minutes of incuba-
tion with mouse–anti rabbit antibody phycoerythrin-labeled (Southern
Biotech, Uithoorn, the Netherlands) and measured by FACSCalibur
(Epics Elite; Coulter Electronics, Mijdrecht, the Netherlands). Data
analysis was performed using Kaluza software (Beckman Coulter
Nederland BV, Woerden, the Netherlands).
CXCL12 Enzyme-Linked Immunosorbent Assay
Medium from confluent MS5, HS27a, PC3-luc, and MDA-MB-231
cell lines were sampled at 48 hours after plating in 24-well plates
and centrifuged to remove cell debris. CXCL12 levels in medium were
assayed with the Quantikine Human CXCL12/SDF1α Immunoassay
kit (R&D Systems, Abingdon, United Kingdom) according to the
manufacturer’s instructions.Measured levels were expressed as picograms
CXCL12 per 1 mg of protein in cell lysate.
Cell Viability Assay
PC3-luc cells were plated in 96-well plates and allowed to attach for
3 to 5 hours and then the medium was exchanged for MS5-derived
culture supernatant and cells were treated with increasing docetaxel con-
centrations (0.1-1 μM) alone or combined with 25 μg/ml AMD3100
or 1:100 anti-hCXCL12 antibody. Survival of cells at day 3 was assessed
by 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT; Sigma)
as described previously [24].
Figure 1. (A) Viability of PC3-luc cells after docetaxel treatmentwith orwithout the presenceofMS5 stromal cell line. (B) Apoptosis of PC3-luc
cells after docetaxel treatment with orwithoutMS5 stromal cell line. (C) Exemplary figures presenting the assessment of PC3-luc cell viability
by fluorescence microscopy (40×). The nuclei (blue, DAPI) are round and intact with visible nucleoli in viable cells, whereas nuclei of apop-
totic PC3-luc cells are condensed and fragmented. Cytoplasm visualized in red (DiI) shows regular structure in viable cells, whereas it is
condensed in apoptotic cells. (D) Exemplary pictures representing the assessment of apoptosis of PC3-luc cell line obtained by fluorescence
microscopy (40× magnification). Apoptotic cells, defined by chromatin condensation and presence of apoptotic bodies, are indicated by
arrows. *P < .05, **P < .005, ***P < .0005.
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Apoptosis Assay
PC3-luc cells were plated in 96-well plate with or without precultured
MS5 stromal monolayer. Once attached, cells were treated with increas-
ing docetaxel concentrations (0.1-1 μM) alone or combined with 25 μg/
ml AMD3100 or 1:100 anti-hCXCL12 antibody. MS5 cells alone were
treated with all conditions as well to assess the background level of apop-
tosis of stromal cells. After 40 hours, acridine orange was added to each
well to distinguish apoptotic from viable cells. The intensity of apoptotic
staining was assessed by fluorescence microscopy, and apoptosis was
defined based on the chromatin condensation and presence of apop-
totic bodies. For every condition in coculture, the background level of
stromal cells apoptosis was extracted to assess the apoptosis of PC3-luc
cells only. At least 300 PC3-luc cells per condition were scored. Results
are expressed as a percentage of apoptotic cells.
Tumor Xenografts and In Vivo Treatment
Male Hsd:Athymic Nude-Foxn1nu 6 to 8 weeks old were injected
subcutaneously with 3 × 106 PC3-luc cells in 100 μl of PBS into the
dorsal region. Tumor size was measured three times per week with a
caliper. All experiments were performed under anesthesia by isoflurane
inhalation (3% for induction, 1.5% for maintenance) and approved by
the ethical committee of the University of Groningen, the Netherlands.
At day 14 after inoculation, tumors were established (ranging from 100
to 200mm3, calculated as 100% of tumor size), and mice were random-
ized into four treatment groups: 1) sterile water intraperitoneally (ip)
daily five times per week (control group, n = 9), 2) docetaxel 10 mg/
kg ip once weekly and sterile water ip on the remaining 4 days (n = 5),
3) AMD3100 3.5 mg/kg ip daily five times per week (n = 9), and 4)
combination treatment of docetaxel and AMD3100 (n = 6). After
5 weeks of treatment, or when humane end points (ulceration or tumor
size >2 cm3) were reached, animals were killed and tumors were
excised, weighed, formalin-fixed and paraffin-embedded (FFPE), and
subjected to immunohistochemical staining with rabbit anti–human
CXCR4 and mouse anti–human CXCL12 antibodies (Abcam).
Bioluminescent Imaging of Tumor Growth
Tumors were imaged twice weekly with an IVIS bioluminescent
camera (Caliper Life Sciences) 10 minutes after injection with 150 mg/
kg D-luciferin (Caliper Life Sciences) with the following camera settings:
f/stop1, small binning, and 10 seconds of exposure time. Data were
analyzed with LivingImage 3.0 (Caliper Life Sciences).
Human Tumor Tissue Collection and
Immunohistochemical Staining
Archival tissue specimens from primary prostate tumors, lymph
node, and bone metastases were obtained from the University Medical
Center Groningen in the Netherlands. Primary prostate cancer tissues
(Gleason stage 6-9) were randomly selected from 15 radical prostatec-
tomies between 2009 and 2010. Bone metastasis specimens (Gleason
stage 8-10) of 15 patients were randomly obtained as biopsies for a
Figure 2. (A) Membrane expression of CXCR4 on PC3-luc (left panel) and MDA-MB-231 (right panel) cancer cell lines presented as mean
fluorescence intensity (FL2-H/PE) of cells stained with (dark-gray histogram) or without (light-gray histogram) CXCR4 antibody. (B) Con-
stitutive levels of CXCL12 produced by mouse (MS5) and human (HS27a) stromal cell lines. (C) Adhesion of PC3-luc cells to the layer of
murine stromal cells (MS5) in time, in the presence or absence of 25 μg/ml AMD3100. (D) Quantification of PC3-luc cell migration toward
10−7 M CXCL12 with or without 25 μg/ml AMD3100. *P = .005, **P = .0001.
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single metastatic lesion or from tumor tissue obtained after neurosurgery
or orthopedic surgery in symptomatic bone metastases. Lymph node met-
astatic tissue (Gleason score 6-10) was randomly obtained from nodal
staging in 15 patients between 2005 and 2007.Only clinical cases without
neoadjuvant androgen deprivation were selected. All tissue specimens
were encoded with unique numbers. According to Dutch law, no fur-
ther institutional review board approval was required (www.federa.org).
FFPE tissue specimens weremounted on slides as a whole tissue sections
and stained with hematoxylin and eosin. CXCR4 expression was assessed
by staining with rabbit anti-human CXCR4 antibody (Abcam), secondary
goat anti-rabbit antibody conjugated to peroxidase (DAKO, Heverlee,
Belgium), and subsequent tertiary rabbit anti-goat conjugated to peroxidase
(DAKO). Staining was visualized by 3,3′-diaminobenzidine. FFPE cervical
cancer cells (HeLa) overexpressing CXCR4 served as a positive control.
Quantification of Immunohistochemical Staining
The intensity of CXCR4 and CXCL12 staining was semiquantita-
tively scored in scale ranging from 0 (no staining), 1 (weak intensity),
2 (moderate intensity), to 3 (strong intensity) in five randomly dis-
tributed fields of view (40×) per sample. Subsequently, whole samples
were classified as positive or negative, based on the sum of all intensity
scores per specimen. When the sum of all scores per sample was higher
than 5, the sample was defined as CXCR4- or CXCL12-positive.
Statistical Analysis
All in vitro experiments were repeated three times. Results were
expressed as mean ± SD. Statistical analysis was performed using the
2-tailed t test for parametric data or with χ2 test for categorical values.
P < .05 was considered statistically significant. Statistical analysis was
performed with GraphPad Prism 5 software.
Results
Stromal Cells Protect Prostate Cancer Cells from
Docetaxel-Induced Cytotoxicity
The influence of stromal cells on viability of PC3-luc on docetaxel
(Figure 1, A and C ) was evaluated with a fluorescence-based cell viabil-
ity assay. PC3-luc cells cultured alone were sensitive to docetaxel in
Figure 3. (A, B) Viability of PC3-luc (A) or MDA-MB-231 (B) cells, cultured alone (left panels), with MS5 stromal cell lines (middle panels)
or with HS27a stromal cell line (right panels) and treated for 40 hours with docetaxel alone or in combination either with AMD3100 or with
anti-CXCL12 antibody. (C) Viability of PC3-luc cells culturedwithMS5-derivedmedium after treatment with docetaxel alone or in combination
with AMD3100 or CXCL12 antibody assessed by MTT assay. *P < .5, **P = .005, ***P < .0005.
Neoplasia Vol. 14, No. 8, 2012 AMD3100 Sensitizes Prostate Cancer to Chemotherapy Domanska et al. 713
a dose-dependent manner with a survival of 14% ± 5.1% at 1 μM
docetaxel. In contrast, prostate cancer cells showed much higher levels
of viability in the presence of stroma (P < .0001). After incubation with
1 μM docetaxel, 61.8% ± 3.4% viable cells remained.
The stromal layer seemed to protect PC3-luc cells by preventing
induction of their apoptosis on chemotherapy (Figure 1, B and D).
At 1 μM docetaxel, 83% ± 5.5% apoptosis in PC3-luc cultured alone
compared with 53% ± 6.5% apoptosis in PC3-luc in the presence of
mouse stromal monolayer (P < .005) was found.
Tumor-Stroma Interactions in Coculture Are CXCR4/
CXCL12 Dependent
The expression of CXCR4 on PC3-luc was shown by FACS anal-
ysis (Figure 2A), where the mean fluorescence intensity (MFI) reached
9.83 ± 2.5, whereas the MFI of the control sample was 2.31 ± 0.7
(P = .0001). The CXCR4-expressing breast cancer cell line MDA-
MB-231 served as control (MFI 15.20 ± 1.34 vs MFI of negative con-
trol 3.96 ± 0.93, P = .0005). Moreover, as shown by ELISA assay,
CXCL12 was constitutively expressed in culture medium derived from
both MS5 (1547.42 ± 731.89 pg/1 mg protein) and HS27a (173.74 ±
106.18 pg/1 mg protein) cell lines (Figure 2B). Both in the PC3-luc
and MDA-MB-231 cell culture media, CXCL12 levels were below the
mean minimum detectable dose of the ELISA kit, given as 18 pg/ml
(data not shown).
Next, the interaction between stromal cells and PC3-luc in a co-
culture model was shown to be CXCR4 dependent in a cell adhesion
assay. About 100% of PC3-luc cells were attached to the stroma layer
24 hours after plating, Treatment with 25 μg/ml AMD3100 reduced
the percentage of PC3-luc cells attached to the stroma layer to 43.0% ±
9.7% (P < .0001) at 24 hours (Figure 2C). As the primary function of
the CXCR4 receptor expressed on prostate cancer cells is induction
of cell migration, the Transwell migration assay was performed to test
the receptor functionality (Figure 2D). PC3-luc cells migrated toward
the gradient of CXCL12 (173 ± 19 cells migrated), and this process
could be inhibited (P = .02) by preincubating the cells with 25 μg/ml
AMD3100 (116 ± 20 cells migrated).
CXCR4/CXCL12 Inhibition Sensitizes Prostate Cancer Cells
to Docetaxel Treatment In Vitro
To show that the reduced docetaxel cytotoxicity in the presence of
stroma was related to the CXCR4/CXCL12 axis, the docetaxel treatment
was combined with 25 μg/ml AMD3100 (Figure 3A, left and middle
panels). The addition of AMD3100 abolished the protective stroma
effect and decreased PC3-luc cell viability levels again to 19.9% ±
8.7% (P = .001). Similarly, the inhibition of CXCL12 with anti-
CXCL12 antibody resulted in sensitization of prostate cancer cells to
docetaxel in the presence of stromal cells (P < .0001). In PC3-luc cells
cultured alone, no differences in cell viability were found between treat-
ments with docetaxel alone and combined with AMD3100 or anti-
CXCL12 antibody. These results were confirmed by the apoptosis assay,
where CXCR4/CXCL12 inhibition sensitized PC3-luc cocultured with
mouse stromal cell line to docetaxel (data not shown).
Human bone marrow–derived stromal fibroblasts HS27a cell line
(Figure 3A, right panel ) was also shown to protect PC3-luc for docetaxel-
induced cytotoxicity (19% ± 6% of viable cells in the presence of
HS27a vs 4% ± 1% of viable tumor cells in the absence of HS27a) after
1 μM docetaxel treatment (P = .02). The stromal protection from
docetaxel was neutralized both by treatment with AMD3100, lowering
PC3-luc cell viability to 10% ± 2% (P = .04), and by anti-CXCL12
antibody, resulting in 10% ± 1.7% of viable cells (P = .049).
The same role of CXCR4/CXCL12 signaling in the stromal cell–
mediated effect was shown for the MDA-MB-231 breast cancer cell line
(Figure 3B). MDA-MB-231 cells treated with docetaxel showed 12% ±
4% viable cells after 1 μM docetaxel (left panel ). However, in the pres-
ence of MS5 stroma cells, 39% ± 8% of MDA-MB-231 cells remained
viable cells after 1 μM docetaxel (P = .01). Both AMD3100 and anti-
CXCL12 antibody treatment in the presence of mouse stroma seemed
to sensitize breast cancer cells (middle panel ); tumor cell viability fell to
Figure 4. (A) Tumor volumes expressed as a percentage of tumor growth related to volume at the start of treatment. *P = .01. (B)
Representative BLI images of mice from respective treatment groups at days 0, 19, and 35 after the start of treatment.
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21% ± 7% (P = .04) and 12% ± 6% (P = .02). This sensitizing effect
was absent when MDA-MB-231 cells were cultured alone. Similar re-
sults were observed when MDA-MB-231 cells were cocultured with
human stromal cells (right panel ). Both AMD3100 (P = .0005) and anti-
CXCL12 (P = .004) antibody sensitized breast cancer cells to docetaxel.
Finally, the conditioned medium of mouse stroma cells harvested
after 48 hours of culture seemed to protect PC3-luc cells from docetaxel
(Figure 3D), and this effect could be reversed by treatment with both
CXCR4 inhibitor (P = .006) and with CXCL12-blocking antibody
(P = .008), as shown by MTT assay.
AMD3100 Sensitizes Prostate Cancer to Docetaxel In Vivo
Finally, to prove a role of CXCR4/CXCL12 signaling in chemo-
sensitivity of prostate cancer cells in the in vivo setting, treatment of
docetaxel was combined with AMD3100 in a subcutaneous xeno-
graft model of prostate cancer (Figure 4). After 19 days, mice treated
with placebo or AMD3100 had reached the defined humane end
point because of tumor size (>2 cm3) and/or tumor ulceration.
Mice treated with docetaxel and the combination of docetaxel and
AMD3100 showed delayed tumor growth compared with that of the
control group (P < .04 and P < .03, respectively). Tumors in mice
treated with docetaxel or the combination of docetaxel and AMD3100
were initially, until 21 days, growing at comparable rates. Thereafter,
tumors in mice treated with docetaxel continued growing, reach-
ing 572% ± 193% of the initial tumor size at the end of experiment
(day 35), whereas tumors treated with the combination of docetaxel
and AMD3100 grew slower, reaching 235% ± 47% of the initial tumor
size (P = .01).
Figure 5. (A) Representative images of immunohistochemical staining of PC3-luc xenografts with hematoxylin and eosin, CXCR4 and
CXCL12 (as indicated in rows) from respective treatment groups (as indicated in columns). (B) Quantification of CXCR4 (left panel) and
CXCL12 (right panel) staining. *P ≤ .0004, **P < .0001 compared with control.
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Docetaxel Therapy Causes Increased CXCR4 Expression in
Prostate Cancer Cells In Vivo
Although mice were only engrafted with solid tumors, histology of
the excised tumors revealed that the tumors were extensively invaded
by spindle-shaped stromal cells with small nuclei (Figure 5). CXCR4
staining revealed that only 20% of specimens from the control group
showed CXCR4 expression, whereas in docetaxel-treated group 50%
of samples were CXCR4-positive (P < .0001). CXCL12 staining
showed that, in 25% of control tumor specimens, CXCL12 was ex-
pressed, whereas after treatment with AMD3100 alone or in combi-
nation with docetaxel, CXCL12 expression was present in 50% of
specimens (P = .0004). In the docetaxel-treated group, all the tumor
specimens were CXCL12-negative (P < .0001 vs control).
Bone Metastatic Lesions from Prostate Cancer Patients
Show Increased Expression of CXCR4
Finally, the expression of CXCR4 in unpaired human prostate can-
cer specimens obtained from primary tumors, lymph node, and bone
metastases was analyzed. Immunohistochemical staining showed that
all the specimens from primary prostate cancer lesions were CXCR4-
negative, whereas 13% of the samples derived from lymph node meta-
static lesions showed cytoplasmic CXCR4 staining (P = .0002 vs
primary tumor samples). Strikingly, 67% of the bone marrow specimens
with tumor involvement showed CXCR4 expression (P < .0001 vs
primary tumors). Notably, as shown in Figure 6, nuclear localization
of CXCR4 was observed in tumor cells present in the bone lesions,
as opposed to primary and lymph node–localized tumor cells, which
showed mainly cytoplasmic staining.
Discussion
In this study, we demonstrated that the stromal microenvironment
protects PC3-luc prostate cancer cells from docetaxel chemotherapy.
Inhibition of CXCR4 with AMD3100 sensitized prostate cancer cells
for docetaxel in the presence of stromal cells in in vitro and in vivo
models. Moreover, our exploratory study in prostate cancer patient speci-
mens showed that CXCR4 is upregulated in bone marrow metastatic
lesions compared with primary lesions and lymph node metastases.
The chemoprotective role of stromal cells has been widely acknowl-
edged as one of the crucial factors directing the response of various
types of cancer cells to conventional treatment [23]. Soluble factors
released by stromal cells, such as CXCL12, attract CXCR4-expressing
cancer cells to the stromal microenvironment. Here, they are exposed
to multiple stroma-derived factors, including interleukin 6 and trans-
forming growth factor β, which have been shown to exert a prosurvival
effect on breast, pancreatic, and melanoma tumor cells [25–27]. In
this way, the specific microenvironmental niche protects CXCR4-
expressing cancer cells from genotoxic stress, such as chemotherapy
[23,28]. Indeed, several preclinical in vivo studies with leukemic
mouse models have demonstrated that interaction of CXCR4-positive
leukemic cells with the CXCL12-rich bone marrow microenvironment
protects leukemic cells from chemotherapy [6,10]. Interestingly, pros-
tate cancer cells, like CXCR4-expressing leukemic cells, are also home
to the CXCL12-expressing niches [14,28,29]. On the basis of this, we
postulated that stromal microenvironment protects prostate cancer
cells from chemotherapy through CXCR4/CXCL12 interaction.
Our study has shown that both mouse and human bone marrow–
derived stromal cells protect prostate cancer cells from docetaxel-
induced toxicity in vitro. Moreover, we have demonstrated that the
interaction between prostate cancer cells and stroma is CXCR4/
CXCL12 dependent and that it is directly conferred by soluble CXCL12
released by stromal cells. Our results are supported by a recently pub-
lished study, in which in a prostate cancer mouse model CXCR4-
positive tumor cells were shown to home in to the CXCL12-rich bone
marrow niche [14].
Figure 6. Representative images of CXCR4 immunohistochemical staining on human prostate cancer specimens from primary tumors
(P), lymph node metastasis (LNM), and bone metastasis (BM) and quantification of CXCR4 staining in respective lesions (lower right
panel). *P ≤ .0002 compared with primary tumor.
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To test whether targeting CXCR4 sensitizes prostate cancer cells
to chemotherapy by disrupting their CXCR4/CXCL12–dependent
interaction with stroma, we used AMD3100, a CXCR4 inhibitor
approved by the Food and Drug Administration. AMD3100 is used
for mobilization of HSCs from the bone marrow to peripheral blood in
non–Hodgkin lymphoma and multiple myeloma [30]. It exerts the
mobilization effect by blocking the CXCR4-dependent interaction be-
tween HSCs and bone marrow stroma. In our in vitro model, indeed,
AMD3100 disrupted the interaction between prostate cancer cells and
bone marrow stroma, sensitizing the former to docetaxel. Our xeno-
graft models showed that this finding persisted in the in vivo setting
by showing a clear chemosensitizing effect of CXCR4 inhibition in
mice treated with a combination of AMD3100 and docetaxel. Treat-
ment with AMD3100 alone did not affect the tumor growth. Studies
investigating the direct effect of drugs interfering with the CXCL12/
CXCR4 axis on tumor growth show conflicting results, and differences
between different drugs were described. In a prostate cancer mouse
model, CXCR4-positive PC3 tumors transfected with Bcl-2 or with
empty vector were treated with the peptide antagonist CTCE-9908.
Although Bcl-2–overexpressing tumors were sensitive to CXCR4 in-
hibition, the wild-type tumors showed no significant tumor growth
delay on CTCE-9908 treatment [31]. In addition, AMD3100 mono-
therapy in other tumor types, such as a breast cancer metastatic mouse
model [32] and a mouse model of acute myeloid leukemia [10], showed
no differences in tumor growth between vehicle and AMD3100 treat-
ment, although in the latter study, AMD3100 sensitized mice to
bortezomib and cytarabine therapy. Two other studies using breast
cancer mouse models [13,33] showed that treatment of the mice
CTCE-9908 resulted in inhibition of the growth rate of primary tumor.
In orthotopic glioma mouse models treatment with 1.25 mg/kg
AMD3100 showed tumor growth inhibition in mice [34], whereas in
other studies, treatment with doses of 10 and 5 mg/kg, respectively,
did not [35,36]. On the basis of these studies, it seems that treatment
with CTCE-9908 monotherapy might have more repressing effect on
tumor growth than that with AMD3100. Our in vivo data are also
supported by in vitro results, clearly showing that AMD3100 therapy
alone does not have a cytotoxic effect on PC3-luc cells because they
can be chemosensitized by CXCR4 inhibition only in the presence of
stroma. Moreover, CXCL12 was not expressed by investigated cancer
cells, excluding the possibility of the direct toxicity of AMD3100 due
to the autocrine stimulation loop.
The rationale for the chemosensitization of prostate cancer by
CXCR4 inhibition was provided by a study of acute promyelocytic
leukemia mouse model. There, AMD3100 treatment resulted in mobi-
lization of acute promyelocytic leukemia cells from the protective bone
marrow microenvironment and increased tumor cell death from
chemotherapy [6]. These preclinical studies provided proof-of-concept
for phase 1/2 clinical trials in which patients with relapsed AML
[37,38] and CLL [39] received intensive chemotherapy plus escalating
doses of AMD3100. These studies demonstrated that AMD3100
combined with conventional chemotherapy is safe and does not affect
hematological recovery, dispelling the common fear that mobilized
normal HSCs will be affected by chemotherapy. Moreover, the 56% of
the 1-year overall survival in 34 patients with AML treated with
AMD3100 4 hours before mitoxantrone, etoposide, and cytarabine is a
very promising result.
For solid tumors, the chemosensitization effect was also found in
a transgenic breast cancer mouse model [13]. Mice treated with the
combination docetaxel and CXCL12 analog CTCE-9908 showed a
38% decreased tumor volume—a larger effect than that observed with
docetaxel alone. In glioma-bearing mice, treatment of AMD3100
synergized with subtherapeutic doses of 1,3-bis(2-chloroethyl)-1-
nitrosourea, resulting in enhanced tumor regression [35]. In our study,
AMD3100 sensitized both CXCR4 positive prostate cancer (PC3-luc)
and breast cancer (MDA-MB-231) cells line after treatment with
docetaxel, suggesting that targeting CXCR4 can be of additional value
in a wide range of CXCR4-expressing cancers.
To analyze the potential relevance of our findings, we evaluated the
CXCR4 expression levels in an unpaired set of prostate cancer patient
specimens coming from either primary tumors or metastatic lesions.
Our results showed that CXCR4 expression is higher in bone metas-
tases compared with primary tumor tissue, whereas this up-regulation
was not observed in such an extent in lymph node metastatic lesions.
These results are compatible with the findings of Shiozawa et al. [14]
and underscore the importance of the unique local microenvironment
in the bone marrow for the biologic behavior of prostate cancer cells.
Interestingly, immunostaining of prostate tumors from the docetaxel-
treated xenografted mice showed an up-regulation of CXCR4 receptors
compared with the untreated tumors. Increased CXCR4 expression
can potentially lead to cancer cells with heightened invasive capac-
ity. Comparable results were found by targeting the VEGF pathway,
either by anti-VEGFR2 antibody DC101, or multitargeted anti-
angiogenic kinase inhibitor sunitinib, or by Vegf-A gene knockout
in mouse models of pancreatic neuroendocrine carcinoma and glio-
blastoma [40]. Besides antitumor effects, tumor adaptation was con-
comitantly elicited and progression to higher stages of malignancy
occurred, in some cases involving increased lymphatic and distant
metastasis. These observations support further exploration of adding
CXCR4 inhibitors to conventional therapy.
In summary, our study showed that CXCR4 inhibition sensitizes
prostate cancer cells to docetaxel, both in vitro and in vivo. Current
treatment strategies for metastasized prostate cancer with chemother-
apy, radiotherapy, or hormonal therapy neglect the interaction of
cancer cells with the protective microenvironment. Disrupting this
interaction to sensitize cells to chemotherapy is therefore a potentially
attractive strategy. Our findings should set the stage for clinical trials
with combined treatment of conventional chemotherapy and CXCR4
antagonists, with the ultimate aim of improving treatment results in
prostate cancer patients.
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